17.23
-0.18(-1.03%)
Currency In USD
| Previous Close | 17.41 |
| Open | 17.38 |
| Day High | 17.42 |
| Day Low | 16.81 |
| 52-Week High | 21.79 |
| 52-Week Low | 11.35 |
| Volume | 30,068 |
| Average Volume | 123,106 |
| Market Cap | 644.75M |
| PE | 11.97 |
| EPS | 1.44 |
| Moving Average 50 Days | 18.49 |
| Moving Average 200 Days | 15.88 |
| Change | -0.18 |
If you invested $1000 in Entrada Therapeutics, Inc. (TRDA) since IPO date, it would be worth $719.42 as of December 30, 2024 at a share price of $17.23. Whereas If you bought $1000 worth of Entrada Therapeutics, Inc. (TRDA) shares 2 years ago, it would be worth $1,274.41 as of December 30, 2024 at a share price of $17.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2024 12:00 PM GMT
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets l
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 05, 2024 12:00 PM GMT
– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clin
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
GlobeNewswire Inc.
Oct 09, 2024 11:00 AM GMT
– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented